Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx

• Published in: Diagnostics (Basel) Vol. 14; no. 1; p. 97
• Main Authors: Chiru, Elena Diana, Oseledchyk, Anton, Schoetzau, Andreas, Kurzeder, Christian, Mosimann, Raphael, Vetter, Marcus, Grašič Kuhar, Cvetka
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31-12-2023; MDPI
• Subjects: Breast cancer; Cancer therapies; Chemotherapy; Clinical medicine; Decision making; Disease; Endocrine therapy; Fatalities; Genes; genomic assay; genomic risk; Hypotheses; Hypothesis testing; Metastasis; Oncology; oncotype; Patients; Population; recurrence score; Tumors; United States > US; Exact Sciences; genomic risk; clinical risk; oncotype; changes in chemotherapy; oncotype DX; breast cancer; TAILORx; genomic assay; oncotype RS; recurrence score; chemotherapy
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14010097

In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2-) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50 years with an intermediate Oncotype DX recurrence score (RS 11-25). The aim of the present study was to determine if the TAILORx findings, including the changes in the RS categories, impacted CHT use in the intermediate RS (11-25) group in daily practice, as well as to identify the main factors for CHT decisions. We conducted a retrospective study on 326 BC patients (59% node-negative), of which 165 had a BC diagnosis before TAILORx (Cohort A) and 161 after TAILORx publication (Cohort B). Changes in the RS categories led to shifts in patient population distribution, thereby leading to a 40% drop in the low RS (from 60% to 20%), which represented a doubling in the intermediate RS (from 30% to 60%) and an increase of 5% in the high RS (from 8-10% to 15%). The overall CHT recommendation and application did not differ significantly between cohort B when compared with A (19% vs. 22%, resp.,
= 0.763). In the intermediate RS (11-25), CHT use decreased by 5%, while in the high-risk RS category (>25), there was an increase of 13%. The tumor board recommended CHT for 90% of the patients according to the new RS guidelines in cohort A and for 85% in cohort B. The decision for CHT recommendation was based on age (OR 0.93, 95% CI 0.08-0.97,
= 0.001), nodal stage (OR 4.77, 95% CI 2.03-11.22,
< 0.001), and RS categories (RS 11-25 vs. RS 0-10: OR 0.06 (95% CI 0.02-0.17),
< 0.001; RS > 26 vs. RS 11-25: OR 618.18 95% CI 91.64-4169.91,
< 0.001), but did not depend on the cohort. In conclusion, while the tumor board recommendation for CHT decreased in the intermediate RS category, there was an increase being reported in the high RS category, thus leading to overall minor changes in CHT application. As expected, among the younger women with intermediate RS and unfavorable histopathological factors, CHT use increased.